Home Search Abstracts Browse Sessions Program Committee Conference Webcasts Contact Us

Session 62   Poster Abstracts
Primary Infection: Treatment Trials and STIs
Tuesday, 1:30 - 3:30 pm
Poster Hall
395Structured Treatment Interruptions in Primary HIV Infection: Final Results of the Multicenter Prospective PRIMSTOP Pilot Trial
B Hoen*1, I Fournier2, I Charreau2, C Lacabaratz3, M Burgard4, C Arvieux5, E Bouvet6, F Pariente2, J P Aboulker2, A Venet3, C Rouzioux4, F Raffi7, and the Primstop study group
1Univ. Hosp., Besançon, France; 2INSERM SC10, Villejuif, France; 3Univ. Paris Sud, Le Kremlin-Bicêtre, France; 4Univ. Hosp. Necker, Paris, France; 5Univ. Hosp., Rennes, France; 6Univ. Hosp. Bichat, Paris, France; and 7Univ. Hosp., Nantes, France
396Determination of HIV-specific CD8+ and CD4+ Responses in Structured Treatment Interruptions in Primary HIV Infection: Results of the Multicenter Prospective Pilot Trial PRIMSTOP
C Lacabaratz-Porret*1, B Hoen2, A Urrutia1, A Rodallec1, A Compagnucci3, M Burgard4, C Rouzioux4, A Venet1, and the Primstop study group
1INSERM E0109, Univ. Paris Sud, Le Kremlin Bicêtre, France; 2Univ. Hosp., Besançon, France; 3Hosp. Hôtel Dieu, Paris, France; and 4Hosp. Necker, Paris, France
397
HIV-1 RNA Viral Load Dynamics after Discontinuation of Early and Effective HAART Initiated During Primary HIV-1 Infection
L Desquilbet*1, C Goujard1, C Deveau1, M Sinet1, M L Chaix2, A Venet1, C Rouzioux2, J-F Delfraissy1, L Meyer1, and PRIMO Study Group
1Le Kremlin Bicetre, France and 2Paris, France
398
Clinical Characteristics and Treatment Uptake in Patients Newly Infected with HIV Identified over a 1-year Period: The Phaedra Collaborative Cohort
T Ramacciotti*1, D Smith1, M Johnston2, E Pae3, M Bloch4, E Rosenberg2, J Kaldor1, B D Walker2, and The Boston-Sydney PHI Study Group
1Natl. Ctr. in HIV Epidemiology and Clin. Res., Univ. of New South Wales, Sydney, Australia; 2Massachusetts Gen Hosp, Boston USA; 3Fenway Community Hlth. Ctr., Boston, MA, USA; and 4Holdsworth House Clin., Sydney, Australia
399Virological and Immunological Predictors of Time to Initial Viral Suppression and Viral Rebound in a Randomised Trial of Combination Therapy in Primary HIV Infection followed by Treatment Interruption
D Smith1, P Grey*1, K Petoumenos1, J Zaunders2, A Kelleher2, P Cunningham2, A Carr3, M Bloch4, R Finlayson5, R McFarlane6, J Kaldor1, D Cooper1, and The Pulse Study Group
1Natl. Ctr. in HIV Epidemiology and Clin. Res., Univ. of New South Wales, Sydney, Australia; 2Ctr. for Immunology, St Vincent's Hosp., Sydney, Australia; 3St. Vincent's Hosp., Sydney, Australia; 4Holdsworth House Gen. Practice, Sydney, Australia; 5Taylor Square Private Clin., Sydney, Australia; and 6407 Doctors, Sydney, Australia
400Long-term Control of HIV-1 RNA Replication following a Unique Supervized Treatment Interruption and Mycophenolate Mofetil Therapy in Patients Treated with HAART since Primary HIV-1 Infection
G P Rizzardi1, G Guaraldi2, A Lazzarin1, G Pantaleo3, and G Tambussi*1
1HSR Hosp San Raffaele, Milan, Italy; 2Univ. Reggio-Modena, Italy; and 3CHUV, Lausanne, Switzerland